SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061556
Filing Date
2023-11-09
Accepted
2023-11-09 08:08:16
Documents
13
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K labp-20231109.htm   iXBRL 8-K 46724
2 EX-99.1 labp-ex99_1.htm EX-99.1 137759
  Complete submission text file 0000950170-23-061556.txt   310957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20231109.xsd EX-101.SCH 2478
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20231109_lab.xml EX-101.LAB 13350
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20231109_pre.xml EX-101.PRE 9846
7 EXTRACTED XBRL INSTANCE DOCUMENT labp-20231109_htm.xml XML 4696
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 231390170
SIC: 2834 Pharmaceutical Preparations